"A" letter.
cc Dr McA & File

THE
OREGON
HEALTH
SCIENCES
UNIVERSITY
School of Medicine
Division of Hematology
and Medical Oncology L586

3181 S.W. Sam Jackson Park Rd.
Portland, OR 97201

RECEIVED
AUG 15 1989

August 10, 1989

Grover Bagby, Jr., M.D.
Head of Division
(503) 279-8443

Bruce W. Dana, M.D.
Assoc. Head of Division
(503) 279-8534

John Fitchen, M.D.
(503) 220-8262, ext. 6621

Scott Goodnight Jr., M.D.
(503) 279-8586

W. David Henner, M.D., Ph.D.
(503) 279-5699

Robert Koler, M.D.
(503) 279-7703

Kathryn E. Richert-Boe, M.D.
(503) 220-8262, ext. 5587

Gerald M. Segal, M.D.
(503) 279-8534

Paul Wallace, M.D.
(503) 279-8534

Melissa A. Brown, Ph.D.
(503) 279-5633

Edward J. Keenan, Ph.D.
(503) 279-7593

Michael Riscoe, Ph.D.
(503) 220-8262, ext. 6639

Barbara Sanderson, Ph.D.
(503) 279-5633

Schools:
Dentistry, Medicine and Nursing

Clinical Facilities:
University Hospital (including Doernbecher Hospital for Children) Crippled Children's Division, Outpatient Clinics

Special Research Division; Vollum Institute for Advanced Biomedical Research

Dr. Harmon C. McAllister
The Council for Tobacco Research - U.S.A., Inc.
900 Third Avenue
New York, N.Y. 10022

Dear Dr. McAllister,

I am writing to inquire about the procedures involved in obtaining funding from the Council for Tobacco Research. I am an assistant professor of Medicine at the Oregon Health Sciences University. My major research interests involve studies on the regulation of the hematopoietic growth factor, Interleukin 4 (IL-4). A hallmark of most of these growth and differentiation factors, including IL-4, is their ability to affect a variety of cells in multiple and distinct ways. However, little is known about the molecular basis of this differential action. I am interested in pursuing this question by identifying and comparing genes specifically activated in various IL-4 responsive cells.

Such studies are important in view of the important role of IL-4 in normal hematopoietic cell differentiation and acquisition of immune competence, as well as its postulated role as an anti-tumor agent. I am currently funded by an NIH FIRST award to study transcriptional regulation of the IL-4 gene. However, these funds are limited and do not allow for investigations into other important areas.

I would appreciate information on the application procedure. Thank you for your consideration.

Sincerely yours,

Melissa A. Brown

Melissa A. Brown, Ph.D.
Assistant Professor of Medicine
Division of Hematology/Oncology

Source: https://www.industrydocuments.ucsf.edu/docs/spgb0000